Cost‐effectiveness analysis of different treatment modalities in BCG ‐unresponsive NMIBC
BJU International · 2024-10 · 134 (4) · 582-588
DOI: 10.1111/bju.16332 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 16.03.2024. Verfasst von Constantin Rieger und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Urinary Bladder Neoplasms, Gemcitabine, Deoxycytidine. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Radical cystectomy (RC) is the standard of care (SOC) in BCG‐unresponsive NMIBC and is associated with a significant health‐related quality‐of‐life burden. Recently, promising results have been published on Gemcitabine/Docetaxel, Pembrolizumab, and Hyperthermic Intravesical Chemotherapy (HIVEC) as salvage therapy options trying to increase the rate of bladder preservation. Here, we performed a Cost‐Effectiveness‐Analysis of those treatment modalities. Patients and Methods We developed a Markov model from a payer's perspective drawing on clinical data of single‐arm trials testing intravesical gemcitabine/docetaxel and pembrolizumab in BCG‐unresponsive NMIBC, as well as clinical data from patients receiving hyperthermic intravesical chemotherapy HIVEC ( n = 29) as intravesical salvage chemotherapy at our uro‐oncological centre in Cologne. Costs were simulated utilising a non‐commercial diagnosis‐related groups grouper, utilities were derived from comparable cost‐effectiveness studies. We used a Monte Carlo simulation to identify the optimal treatment, comparing the incremental cost effectiveness ratios (ICERs) at a willingness‐to‐pay threshold of €50 000 (euro)/quality‐adjusted life year (QALY).
Results
Over a horizon of 10 years, gemcitabine/docetaxel, HIVEC, and pembrolizumab were associated with costs of €48 353, €64 438, and €204 580, as well as a gain of QALYs of 6.16, 6.48, and 6.00, resulting in an ICER of €26 482, €42 567, and €184 533 respectively, in comparison to RC with total costs of €21 871 and a gain of QALYs of 5.01. Monte Carlo simulation identified HIVEC as the treatment of choice under assumption of a WTP of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Urologic Oncology, Robot-Assisted and Specialized Urologic Surgery, University of Cologne, Cologne, Germany.
- Faculty of Law, Business and Economics, University of Bayreuth, Bayreuth, Germany.
- Department of Urology, Medical University Vienna, Vienna, Austria.
ORCID-Profile: Constantin Rieger, Enno Storz, David Pfister, Axel Heidenreich
Zitieren
APA
Rieger, C., Schlüchtermann, J., Storz, E., Kastner, L., Pfister, D., & Heidenreich, A. (2024). Cost‐effectiveness analysis of different treatment modalities in BCG ‐unresponsive NMIBC. BJU International, 134(4), 582-588. https://doi.org/10.1111/bju.16332
Vancouver
Rieger C, Schlüchtermann J, Storz E, Kastner L, Pfister D, Heidenreich A. Cost‐effectiveness analysis of different treatment modalities in BCG ‐unresponsive NMIBC. BJU International. 2024;134(4):582-588. doi:10.1111/bju.16332
BibTeX
@article{Rieger2024,
author = {Rieger, Constantin and Schlüchtermann, Jörg and Storz, Enno and Kastner, Lucas and Pfister, David and Heidenreich, Axel},
title = {Cost‐effectiveness analysis of different treatment modalities in BCG ‐unresponsive NMIBC},
journal = {BJU International},
year = {2024},
volume = {134},
number = {4},
pages = {582--588},
doi = {10.1111/bju.16332}
}
EUVIMED